News
Sports
Life
Opinion
Business
Advertise
Obituaries
eNewspaper
Legals
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
NewsOK Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Veracyte Inc
(NQ:
VCYT
)
31.69
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Veracyte Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification
April 17, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023
April 13, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting
April 12, 2023
From
Veracyte, Inc.
Via
Business Wire
A Preview Of Veracyte's Earnings
February 21, 2023
Via
Benzinga
Expert Ratings for Veracyte
January 05, 2023
Via
Benzinga
Biotech And Life Science Trades: Q1 2023 Performance By The Numbers
April 01, 2023
Despite a strong month and a great finish to the quarter, many traders remain cautious about the market. It’s been a volatile time after the collapse of Silicon Valley Bank, but the first quarter of...
Via
Talk Markets
Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners
March 15, 2023
From
Veracyte, Inc.
Via
Business Wire
7 Biotech Stocks That Could Be the Next Big Thing
March 15, 2023
Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough.
Via
InvestorPlace
Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank
March 11, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Earnings Perspective: Return On Capital Employed
November 16, 2022
Via
Benzinga
Double-Digit Sales Growth: Is This Stock a Convincing Buy for Growth Investors?
March 10, 2023
This diagnostics test maker has held up well over the last year.
Via
The Motley Fool
Veracyte to Participate in Upcoming Investor Conferences
February 27, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results
February 22, 2023
From
Veracyte, Inc.
Via
Business Wire
SMID Cap Life Science Update: Are You An Investor Or Trader?
February 20, 2023
Despite choppy trading, there is an upward tilt to life science stocks since the 9/26/22 lows.
Via
Talk Markets
Data Published in “The Red Journal” Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer
February 15, 2023
From
Veracyte, Inc.
Via
Business Wire
Earnings Scheduled For February 22, 2023
February 22, 2023
Companies Reporting Before The Bell • Rio Tinto (NYSE:RIO) is projected to report earnings for its Fiscal Year 2022.
Via
Benzinga
New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment
February 13, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023
February 06, 2023
From
Veracyte, Inc.
Via
Business Wire
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
February 05, 2023
A few small cap biotechs lost momentum last week so now might be the time to take profits. But many of these stocks are favored because of their core technology and favored by funds; time to buy?
Via
Talk Markets
Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium
February 01, 2023
From
Veracyte, Inc.
Via
Business Wire
Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules
February 01, 2023
From
Veracyte, Inc.
Via
Business Wire
Better Long-Term Buy in 2023: Exact Sciences or Veracyte?
January 24, 2023
As cancer screenings are becoming covered more often, both companies stand to gain.
Via
The Motley Fool
Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
January 23, 2023
From
Exagen Inc.
Via
GlobeNewswire
Raymond James Upgrades Natera & Myriad Genetics, While Downgrading This Stock
January 18, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023
January 18, 2023
Via
Benzinga
This Small-Cap Stock Is a No-Brainer Buy
January 18, 2023
This genomic test maker's stock was beaten down in 2022. But it could be heading for a rebound this year.
Via
The Motley Fool
Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis
December 15, 2022
From
Veracyte, Inc.
Via
Business Wire
Veracyte Stock Showing Market Leadership; Earns 93 RS Rating
December 01, 2022
Veracyte shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
January 05, 2023
Via
Benzinga
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
November 11, 2022
Gainers
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.